---
layout: default
title: Brinzolamide
parent: 僅模型預測 (L5)
nav_order: 67
evidence_level: L5
indication_count: 1
---

# Brinzolamide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Brinzolamide: Evaluation Incomplete — No TxGNN Predictions Available

## One-Sentence Summary

Brinzolamide is a topical carbonic anhydrase inhibitor clinically used for open-angle glaucoma and ocular hypertension.
The current Evidence Pack contains **no TxGNN predicted indications**, and the regulatory data for Taiwan shows no approved licenses.
As a result, a full repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not found in regulatory data (clinical use: glaucoma / ocular hypertension) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why Evaluation Cannot Proceed

The Evidence Pack for Brinzolamide (DrugBank: DB01194) is missing two categories of data critical for a repurposing evaluation:

**No TxGNN predictions are available.** The `predicted_indications` field is empty, meaning the graph neural network model did not output any candidate new indications for this drug. Without a target indication, there is nothing to evaluate.

**Mechanism of action (MOA) data is absent.** The `original_moa` field is flagged as a data gap. Based on published pharmacology, Brinzolamide inhibits carbonic anhydrase II (CA-II) in the ciliary processes of the eye, reducing aqueous humor production and thereby lowering intraocular pressure. This known mechanism is not reflected in the current Evidence Pack and cannot be used to reason about mechanistic plausibility for any new indication until TxGNN produces a target.

**Safety and regulatory data are unavailable.** No Taiwan package insert warnings, contraindications, or drug interaction records were retrieved. Without baseline safety profiling, even a preliminary feasibility screen cannot be completed.

---

## Taiwan Market Information

No authorization records found. Brinzolamide is not currently marketed in Taiwan.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is structurally incomplete — there are no TxGNN predicted indications and no MOA data — making it impossible to produce a meaningful repurposing evaluation at this time.

**To proceed, the following is needed:**

1. **Re-run TxGNN pipeline** — Verify whether Brinzolamide (DB01194) was included in the knowledge graph embedding. If the node is absent or isolated, the model will return no predictions. Check graph coverage and re-run if needed.
2. **Resolve Data Gap DG002 (MOA)** — Query the DrugBank API for DB01194 to retrieve mechanism of action, pharmacodynamics, and drug categories.
3. **Resolve Data Gap DG001 (Package Insert)** — Retrieve the Taiwan TFDA package insert PDF to extract approved indications, warnings, and contraindications.
4. **Confirm drug class eligibility** — Brinzolamide is a topically administered ophthalmic agent. Confirm whether the TxGNN model scope includes non-systemic drugs; if not, note this as a model boundary limitation.
5. **Re-generate Evidence Pack** — Once the above gaps are resolved, regenerate the v5 Evidence Pack and re-submit for evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

